Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
Recruiting · NCT06526364 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Basel, Switzerland
View the official record on ClinicalTrials.gov →Interventions studied
All participants will be asked to provide data and samples for collection and analysis.
What this trial is about
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥18
- Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations.
- Signed informed consent form
- In possession of a Healios+Me app compatible smartphone (iOS/Android)
- Corrected close visual acuity of ≥0.5
- Hand motor skills sufficient for using a smartphone
- Ability to follow the study procedures
- Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (\< 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS).
- Enrolled in the SMSC at University Hospital Basel
- There are no specific
Where it is running
1 location listed.
- Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) - Basel, Switzerland